About the Company
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MYOV News
Myovant Sciences Rejects $2.5 Billion Takeover; Now What?
Myovant Sciences is developing drug candidates for ... Meanwhile, the list of potential suitors may be limited. Not many established drug developers have commercial infrastructure built for ...
Roivant Sciences Ltd Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
TAKEDA PHARMACEUTICAL CO LTD's Net Worth
Inc., and Myovant Sciences Ltd.. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive ...
Roivant Sciences Ltd.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Daniel S. Sundheim's Net Worth
Who is Daniel S. Sundheim? Daniel S. Sundheim has an estimated net worth of $1.26 Billion. This is based on reported shares across multiple companies, which include Maplebear Inc., Editas Medicine ...
WAVE Life Sciences Ltd WVE
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Himile Mechanical Science & Technology (Shandong) Co. Ltd. A
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Camlin Fine Sciences Ltd (CAMLINFINE) Share Price
Camlin Fine Sciences Ltd share price was down by -0.64% from the previous closing price of ₹109.30. Who are peers of Camlin Fine Sciences Ltd? The peers of Camlin Fine Sciences Ltd are Pidilite ...
StageZero Life Sciences Ltd. (SZLSF)
TORONTO, ON / ACCESSWIRE / April 5, 2024 /StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA multi ...
JFL Life Sciences Ltd (JFLLIFE) Share Price
JFL Life Sciences Ltd share price was up by 4.65% from the previous closing price of ₹43.00. Who are peers of JFL Life Sciences Ltd? The peers of JFL Life Sciences Ltd are Sun Pharmaceuticals ...
Vita Life Sciences Limited (VLS.AX)
Vita Life Sciences (ASX:VLS) has had a great run on the share market with its stock up by a significant 9.0% over the... Simply Wall St. A Look At The Fair Value Of Vita Life Sciences Limited (ASX ...
WVE Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
Loading the latest forecasts...